27 Jun 2022 13:58
27 June 2022
Medica Group Plc
Result of Annual General Meeting
Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK and Ireland market leader in the provision of teleradiology services, announces that, at its Annual General Meeting held at 11.00am today, all resolutions put to the meeting were duly passed.
Details of the voting are as follows:
Resolution | For/ Discretion (Number of votes) | % For/ Discretion | Against (Number of votes) | % Against | Total votes
| Withheld (Number of votes) | |||||||
Ordinary Business | |||||||||||||
1. | To receive and adopt the annual report, accounts and the auditor's report |
|
|
|
|
|
| ||||||
2. | To approve the Directors' Remuneration Report (excluding Remuneration Policy) |
|
|
|
|
|
| ||||||
3. | To approve the amendments to the rules of the Performance Share Plan |
|
|
|
|
|
| ||||||
4. | To declare a final dividend |
|
|
|
|
|
| ||||||
5. | To re-appoint Grant Thornton UK LLP as auditors |
|
|
|
|
|
| ||||||
6. | To authorise the directors to determine the remuneration of the auditors |
|
100.00 |
0 |
0.00 |
|
| ||||||
7. | To re-elect Roy Davis as a Director |
|
|
|
|
|
| ||||||
8. | To re-elect Joanne Easton as a Director |
|
|
|
|
|
| ||||||
9. | To re-elect Dr Junaid Bajwa as a Director |
|
|
|
|
|
| ||||||
| 10. | To re-elect Stuart Quin as a Director |
|
|
|
|
|
| ||||||
| 11. | To re-elect Richard Jones as a Director |
|
|
|
|
|
| ||||||
| 12. | To elect Barbara Moorhouse as a Director |
|
100.00 |
0 |
0.00 |
|
| ||||||
Special Business | |||||||||||||
| 13. | General authority to allot shares pursuant to Section 551 Companies Act 2006 |
|
|
|
|
|
| ||||||
| 14. | General authority to allot equity securities pursuant to Section 570 Companies Act 2006 |
|
|
|
|
|
| ||||||
15. | General authority to allot equity securities pursuant to Section 570 Companies Act 2006 for the purpose of financing an acquisition or other capital investment |
|
|
|
|
|
| ||||||
16. | Authority to make market purchases of up to 12,242,883 shares |
|
|
|
|
|
| ||||||
17. | To authorise the general meeting to be held on 14 clear days' notice |
|
|
|
|
|
| ||||||
For further information, please contact:
Medica Group Plc: Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer
| +44 (0)33 33 111 222
|
FTI Consulting Victoria Foster Mitchell Sam Purewal
| +44 (0)20 3727 1000 |
Liberum (Joint Broker) Phil Walker Richard Lindley
| +44 (0)20 3100 2000 |
Numis (Joint Broker) Freddie Barnfield Duncan Monteith Euan Brown
| +44 (0)20 7260 1000
|
About Medica Group PLC
Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.
Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.
The Company currently offers two primary services to hospital radiology departments:
· NightHawk - urgent reporting service
· Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.
These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.
Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.
For more information please visit: www.medicagroupplc.com